Brief: Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted To Lp-184 In Multiple Ultra Rare Children’S Cancers
23/09/2024 14:24
Sept 23 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA ANNOUNCES THREE U.S. FDA RARE PEDIATRIC
DISEASE
DESIGNATIONS GRANTED TO LP-184 IN MULTIPLE ULTRA RARE CHILDREN’S
CANCERS
Source text for Eikon: ID:nBw9lFqDSa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments